Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ CCR3 Polyclonal Antibody
Rabbit Polyclonal Antibody
Supplier: Invitrogen™ PA141377
Description
Suggested positive control: antigen standard for CCR3 (transient overexpression lysate), Daudi.
CCR3 (C-C chemokine receptor type 3) binds to eotaxin, eotaxin-3, MCP-3, MCP-4, RANTES, and MIP-1 delta. CCR3 trasnduces a signal by increasing the intracellular calcium ions level. It also serves as an alternative co-receptor with CD4 for HIV-1 infection. Other chemokines play important roles in inflammation and are critical for the recruitment of effector immune cells to sites of infection. Chemokines activate leukocytes by binding to G protein coupled receptors. The ever-growing chemokine receptor subtypes can be divided into 2 major groups, CXCR and CCR, based on the 2 major classes of chemokines.
Specifications
CCR3 | |
Polyclonal | |
Unconjugated | |
CCR3 | |
b-chemokine receptor; CC chemokine receptor 3; C-C chemokine receptor type 3; C-C CKR-3; C-C motif chemokine receptor 3; CC-CKR3; CC-CKR-3; Ccr3; CCR-3; CD193; chemokine (C-C motif) receptor 3; chemokine (C-C) receptor 1,-like 2; chemokine (C-C) receptor 3; CKR3; Cmkbr1l2; CMKBR3; eosinophil CC chemokine receptor 3; eosinophil eotaxin receptor; Macrophage inflammatory protein 1-alpha receptor-like 2; MGC102841; MIP-1 alpha RL2; MIP-1 alphaRL2; probable C-C chemokine receptor type 3 | |
Rabbit | |
Protein G | |
RUO | |
117027, 1232, 12771 | |
-20°C, Avoid Freeze/Thaw Cycles | |
Liquid |
Western Blot | |
0.5 mg/mL | |
PBS with no preservative | |
O54814, P51677, P51678 | |
CCR3 | |
Synthetic peptide corresponding to a portion of human CCR3 protein. | |
100 μg | |
Primary | |
Human, Mouse, Rat | |
Antibody | |
IgG |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction